Approval of the board's resolution on a rights issue

The Extraordinary General Meeting resolved to approve the board's resolution on 12 November 2024 regarding a rights issue of a maximum of 35,729,342 shares, which means an increase of the share capital by a maximum of SEK 7,145,868.40.

The right to subscribe for the new shares shall accrue to the shareholders with preferential rights in relation to the number of shares they previously owned. For each existing share, one (1) subscription right is received. Thirteen (13) subscription rights entitle the holder to subscribe for seventeen (17) shares. The record date at Euroclear Sweden AB for determining which shareholders are entitled to subscribe for shares with preferential rights shall be 4 December 2024. Subscription of shares shall take place during the subscription period from and including 6 December 2024 up to and including 20 December 2024. A subscription price of SEK 1.80 shall be paid for each share subscribed for.

For additional information, please contact:
Anders Månsson
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis

About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.